MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
MapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s overall success. Investors had been hoping ...
July 27, 2026 11:17 AM EDT R&D MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win Ayisha Sharma News Reporter MapLight Therapeutics’ stock $MPLT plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that